Drag a card by its title · ⚙ to size, swap or remove

The company

Tango Therapeutics, Inc.

TNGX · Nasdaq

Health CareBiotechnologyJust started moving

TNGX stood above a rising 150-day average in 48 of the last 52 weekly readings, including each of the last 1 week. It is 1.9% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation: Just started moving
Weeks in an uptrend: 1 in a row
Industry in uptrend: 18% -14 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $19.6M
Officials’ trades on record: 0
Institutions holding: 233 (+47)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 48 of 52 weeks.

21 Apr – 20 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months16

Buyers · sellers0 · 5

Who	Did	Shares	Traded
Adam CrystalPresident, R&D	sold	26,400at $24.45	1 Oct 2026filed 5 Oct 2026
Adam CrystalPresident, R&D	sold	600at $25.32	1 Oct 2026filed 5 Oct 2026
Jessica NewcombPrincipal Accounting Officer	sold	700at $22.80	22 Sep 2026filed 24 Sep 2026
Jessica NewcombPrincipal Accounting Officer	sold	5,100at $23.97	22 Sep 2026filed 24 Sep 2026
Jessica NewcombPrincipal Accounting Officer	sold	2,400at $25.17	22 Sep 2026filed 24 Sep 2026
Adam CrystalPresident, R&D	sold	27,000at $22.37	1 Sep 2026filed 3 Sep 2026
Adam CrystalPresident, R&D	sold	5,267at $26.79	3 Aug 2026filed 5 Aug 2026
Adam CrystalPresident, R&D	sold	21,733at $27.35	3 Aug 2026filed 5 Aug 2026
Adam CrystalPresident, R&D	sold	19,629at $29.34	1 Jul 2026filed 2 Jul 2026
Adam CrystalPresident, R&D	sold	7,371at $30.25	1 Jul 2026filed 2 Jul 2026
Adam CrystalPresident, R&D	sold	6,140at $22.25	1 Jun 2026filed 3 Jun 2026
Adam CrystalPresident, R&D	sold	20,860at $23.06	1 Jun 2026filed 3 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders233+47 on the quarter

New · exited72 · 25

Reported value$6.4B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
RTW INVESTMENTS, LPadded · filed 14 Aug 2026	13,900,620$434.5M	+600,000+4.5%
BlackRock, Inc.added · filed 7 Aug 2026	12,438,444$388.8M	+3,690,399+42.2%
FMR LLCadded · filed 13 Aug 2026	12,333,339$385.5M	+2,427,420+24.5%
FARALLON CAPITAL MANAGEMENT, L.L.C.added · filed 14 Aug 2026	12,277,000$383.8M	+3,179,589+35.0%
Boxer Capital Management, LLCunchanged · filed 14 Aug 2026	10,876,219$340.0M	00.0%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026	9,980,620$312.0M	+4,904,228+96.6%
TCG Crossover Management, LLCreduced · filed 14 Aug 2026	9,081,201$283.9M	-1,449,870−13.8%
TRV GP IV, LLCunchanged · filed 10 Aug 2026	6,374,574$120.2M	00.0%
Paradigm Biocapital Advisors LPadded · filed 14 Aug 2026	6,357,523$198.7M	+2,347,844+58.6%
Siren, L.L.C.added · filed 13 Aug 2026	6,179,364$193.2M	+522,259+9.2%